Euclid Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Euclid Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,810	Closed	-$500K	–	448
2016 Q2	$500K	Sell	5,810 -2,476	-30%	-$214K	0.02%	380
2016 Q1	$659K	Sell	8,286 -12,313	-60%	-$1.11M	0.02%	360
2015 Q4	$2.59M	Buy	+20,599	New	+$2.49M	0.08%	250
2015 Q3	–	Sell	-40,660	Closed	-$5.02M	–	435
2015 Q2	$5.02M	Sell	40,660 -47,840	-54%	-$6.03M	0.1%	239
2015 Q1	$10.4M	Buy	+88,500	New	+$10.6M	0.19%	134
2014 Q4	–	Sell	-121,530	Closed	-$13.7M	–	499
2014 Q3	$13.7M	Buy	121,530 +9,240	+8%	+$880K	0.1%	193
2014 Q2	$10.6M	Sell	112,290 -17,854	-14%	-$1.25M	0.07%	256
2014 Q1	$9.2M	Buy	130,144 +37,690	+41%	+$2.99M	0.07%	253
2013 Q4	$6.87M	Sell	92,454 -5,396	-6%	-$376K	0.06%	300
2013 Q3	$7.42M	Buy	+97,850	New	+$7.79M	0.08%	243

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Euclid Advisors's VRTX Position: Q3 2016 in Review

Euclid Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2016, closing a stake of 5,810 shares — an estimated $500K sold.

Euclid Advisors first reported a position in VRTX in Q3 2013 and held it in 10 quarters. The position peaked at $13.7M in Q3 2014. 490 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

Euclid Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Euclid Advisors sold 5,810 Vertex Pharmaceuticals shares in Q3 2016, an estimated $500K.
Euclid Advisors first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Euclid Advisors's Vertex Pharmaceuticals position peaked at $13.7M in Q3 2014.
490 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.